2-Aryloxy-4-alkylaminopyridines: Discovery of Novel Corticotropin-Releasing Factor 1 Antagonists
Journal of Medicinal Chemistry2008Vol. 51(5), pp. 1385–1392
Citations Over TimeTop 16% of 2008 papers
Yuhpyng L. Chen, R. Scott Obach, John P. Braselton, Michael L. Corman, James T. Forman, Jody Freeman, Randall J. Gallaschun, Robert S. Mansbach, Anne W. Schmidt, Jeffrey Sprouse, F. David Tingley, Elizabeth Winston, David W. Schulz
Abstract
An orally active clinical candidate of corticotropin-releasing factor 1 (CRF 1) antagonist 1 showed a significant positive food effect in dog and human after oral administration. Efforts to address the food effect issue led us to explore and discover compounds in series 2 as orally active CRF 1 receptor antagonists, in which some compounds showed improved physicochemical properties while retaining desired pharmacological properties. Compound 3a (CP-376395) was selected for further development, due not only to its reduced food effects but also its greater efficacy in CNS models. Compound 3a was advanced to the clinic. The synthesis of representative potential candidates and their in vitro, ex vivo, and in vivo data are described.
Related Papers
- → In Vivo Pharmacologic Profile of ONO-1078: A Potent, Selective and Orally Active Peptide Leukotriene (LT) Antagonist(1992)20 cited
- → Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma(2014)2 cited
- → An orally active renin inhibitor(1989)12 cited
- → Pharmacology of (2R, 4R, 5S)-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid (NPC 17742); a selective, systemically active, competitive NMDA antagonist(1993)8 cited
- Studies of an orally active leukotriene antagonist L-649,923 in normal man.(1987)